The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis

Abstract EN

Background.

Recently, the role of microRNAs (miRNAs) in diagnosing cancer has been attracted increasing attention.

However, few miRNAs have been applied in clinical practice.

The purpose of this study was to evaluate the diagnostic efficacy of miRNAs for hepatocellular carcinoma (HCC) at early stages clinically.

Methods.

A literature search was carried out using PubMed, Web of Science, and EMBASE databases.

We explored the diagnostic value of miRNAs in distinguishing HCC from healthy individuals.

The quality assessment was performed in Review Manager 5.3 software.

The overall sensitivity and specificity and 95% confidence intervals (CIs) were obtained with random-effects models through Stata 14.0 software.

And heterogeneity was assessed using Q test and I2 statistics.

Meta-regression and subgroup analyses were conducted based on the sample, nation, quality of studies, and miRNA profiling.

The publication bias was evaluated through Deeks’ funnel plot.

Results.

A total of 34 studies, involving in 2747 HCC patients and 2053 healthy individuals, met the inclusion criteria in the 33 included literature studies.

In the summary receiver operating characteristic (sROC) curve, AUC was 0.92 (95% CI, 0.90–0.94), with 0.84 (95% CI, 0.79–0.88) sensitivity and 0.87 (95% CI, 0.83–0.90) specificity.

There was no publication bias (P=0.48).

Conclusion.

miRNAs in vivo can be acted as a potential diagnostic biomarker for HCC, which can facilitate the early diagnosis of HCC in clinical practice.